American Society of Nephrology Annual Meeting

American Society of Nephrology Annual Meeting

Source:

Barreto EF, et al. PO0007. Presented at: ASN Kidney Week. Oct. 22-25, 2020 (virtual meeting).

Disclosures: Healio Nephrology was unable to determine relevant financial disclosures prior to publication.
December 03, 2020
1 min read
Save

Study finds 30% of patients with AKI do not receive adequate follow-up

Source:

Barreto EF, et al. PO0007. Presented at: ASN Kidney Week. Oct. 22-25, 2020 (virtual meeting).

Disclosures: Healio Nephrology was unable to determine relevant financial disclosures prior to publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Research presented at the virtual ASN Kidney Week suggested 30% of patients hospitalized with AKI received inadequate follow-up, with medical risk factors being the “primary determinants” of care after hospitalization.

“[AKI] affects 20% of hospitalized patients and results in long-term adverse outcomes,” Erin F. Barreto, PharmD, RPh, of the Mayo Clinic in Rochester, and colleagues wrote in a poster. “To limit its complications, post-discharge follow-up is advised. The objective of the study was to evaluate the frequency of appropriate follow-up after discharge among AKI survivors.”

For the study, researchers included 563 patients who had an episode of AKI during hospitalization at the Mayo Clinic (64% had stage 2 AKI; 36% had stage 3) and examined the adequacy of follow-up care. Adequate care was defined by the patient having a serum creatinine level assessment and/or an in-person health care visit within 30 days, 90 days or 1 year after discharge.

They found the 30-day cumulative incidence of follow-up with serum creatinine assessment was 78% and was 80% by provider visit. Follow-up with both serum creatine assessment and a health care provider visit was 70%.

The incidences of both serum creatinine assessment and provider visit increased to 81% within 90 days after discharge and 91% within 1 year after discharge.

“Within 30-days after discharge, only 13% of these stage 2 or 3 AKI survivors saw a nephrologist,” Barreto and colleagues wrote.

Regarding the likelihood of follow-up within 30 days, researchers observed medical risk factors — including higher BMI, lower kidney function at baseline and discharge, higher comorbidity burden, greater AKI severity and longer duration of AKI during hospitalization — more accurately predicted adequate follow-up than did social or demographic characteristics.